 |
Ziyi Wen, PhD
Postdoctoral Associate Email: ziyi.wen@stonybrookmedicine.edu |
Dr. Wen received her Bachelor’s degree in Pharmacy in 2007 and her PhD degree in Pharmaceutics in 2011 from Shenyang Pharmaceutical University, School of Pharmacy. Her research areas include targeting drug delivery from nose to brain using nanotechnologies, targeting delivery systems for tumor therapy, transdermal drug delivery, and modernization of traditional Chinese medicine, among other interests. She also has years of industry experience serving as senior scientist in the R&D department of a world-class pharmaceutical company.
Dr. Wen’s current projects are on pancreatic and lung cancer treatments using novel compounds and drug delivery technologies.
Selected Publications
- Zhiqiang Yan, Fei Wang, Ziyi Wen, Changyou Zhan, Linglin Feng, Yu Liu, Xiaoli Wei, Cao Xie, Weiyue Lu. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor. Journal of Controlled Release. 2011;157 (1), 118-125.
- Ziyi Wen, Zhiqiang Yan, Kaili Hu, Zhiqing Pang, Xufei Cheng, LiangRan Guo, Qizhi Zhang, Xinguo Jiang, Liang Fang, Ren Lai. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration. Journal of Controlled Release. 2011;151 (2), 131-138
- Zhiqing Pang, Huile Gao, Yuan Yu, Liangran Guo, Jun Chen, Shuaiqi Pan, Jinfeng Ren, Ziyi Wen, Xinguo Jiang. Enhanced intracellular delivery and chemotherapy for glioma rats by transferrin-conjugated biodegradable polymersomes loaded with doxorubicin. Bioconjugate Chemistry. 2011;22 (6), 1171-1180
- Zhiqing Pang, Huile Gao, Yuan Yu, Jun Chen, Liangran Guo, Jinfeng Ren, Ziyi Wen, Jinghan Su, Xinguo Jiang. Brain delivery and cellular internalization mechanisms for transferrin conjugated biodegradable polymersomes. International Journal of Pharmaceutics. 2011;415 (1), 284-292
- Liangran Guo, Li Fan, Zhiqing Pang, Jinfen Ren, Yulong Ren, Jingwei Li, Jie Chen, Ziyi Wen, Xinguo Jiang. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. Journal of Controlled Release. 2011;154 (1), 93-102
For a complete list of publications, Click Here.
